Effects of the Dipeptidyl Peptidase-IV Inhibitor Vildagliptin on Incretin Hormones, Islet Function, and Postprandial Glycemia in Subjects With Impaired Glucose Tolerance
- 1 January 2008
- journal article
- research article
- Published by American Diabetes Association in Diabetes Care
- Vol. 31 (1), 30-35
- https://doi.org/10.2337/dc07-1616
Abstract
OBJECTIVE—This study was conducted to determine the effects of vildagliptin on incretin hormone levels, islet function, and postprandial glucose control in subjects with impaired glucose tolerance (IGT).Keywords
This publication has 22 references indexed in Scilit:
- Efficacy and tolerability of vildagliptin in drug-naïve patients with type 2 diabetes (T2DM) and mild hyperglycemiaDiabetologie und Stoffwechsel, 2008
- Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug‐naïve patients with Type 2 diabetesDiabetic Medicine, 2007
- Effects of Dipeptidyl Peptidase-4 Inhibition on Gastrointestinal Function, Meal Appearance, and Glucose Metabolism in Type 2 DiabetesDiabetes, 2007
- Effects of Vildagliptin on Glucose Control Over 24 Weeks in Patients With Type 2 Diabetes Inadequately Controlled With MetforminDiabetes Care, 2007
- Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitusCurrent Opinion in Endocrinology, Diabetes and Obesity, 2007
- Comparison of Vildagliptin and Rosiglitazone Monotherapy in Patients With Type 2 DiabetesDiabetes Care, 2007
- Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetesDiabetes, Obesity and Metabolism, 2007
- Impact of incretin hormones on β-cell function in subjects with normal or impaired glucose toleranceAmerican Journal of Physiology-Endocrinology and Metabolism, 2006
- Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trialThe Lancet, 2006
- Improved Meal-Related β-Cell Function and Insulin Sensitivity by the Dipeptidyl Peptidase-IV Inhibitor Vildagliptin in Metformin-Treated Patients With Type 2 Diabetes Over 1YearDiabetes Care, 2005